Cited by 401Systemic Lupus Erythematosus ResearchBlood Coagulation and Thrombosis MechanismsVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo controlled trial in asymptomatic antiphospholipid antibody-positive individuals.

Erkan, Doruk, Harrison, Melanie J., Levy, Roger, Peterson, Margaret, Petri, Michelle, Sammaritano, Lisa, Unalp‐Arida, Aynur, Vilela, Veronica, Yazici, Yusuf, Lockshin, Michael D.·2007·Arthritis & Rheumatism

DOI 10.1002/art.22663

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To determine the efficacy of a daily dose of 81 mg aspirin in primary thrombosis prevention in asymptomatic, persistently antiphospholipid antibody (aPL)-positive individuals (those with positive aPL but no vascular and/or pregnancy events). METHODS: The Antiphospholipid Antibody Acetylsalicylic Acid (APLASA) study was a multicenter, randomized, double-blind, placebo-controlled clinical trial in which asymptomatic, persistently aPL-positive individuals were randomized to receive a daily dose of 81 mg of aspirin or placebo. In a separate observational and parallel study, asymptomatic, persistently aPL-positive individuals who were taking aspirin or declined randomization were followed up prospectively. RESULTS: In the APLASA study, 98 individuals were randomized to receive aspirin or placebo (mean +/- SD followup period 2.30 +/- 0.95 years), of whom 48 received aspirin and 50 received placebo. In the observational study, 74 nonrandomized individuals were followed up prospectively (mean +/- SD followup period 2.46 +/- 0.76 years); 61 received aspirin and 13 did not. In the APLASA study, the acute thrombosis incidence rates were 2.75 per 100 patient-years for aspirin-treated subjects and 0 per 100 patient-years for the placebo-treated subjects (hazard ratio 1.04, 95% confidence interval 0.69-1.56) (P = 0.83). Similarly, in the observational study, the acute thrombosis incidence rates were 2.70 per 100 patient-years for aspirin-treated subjects and 0 per 100 patient-years for those not treated with aspirin. All but 1 patient with thrombosis in either study had concomitant thrombosis risk factors and/or systemic autoimmune disease at the time of thrombosis. CONCLUSION: Our results suggest that asymptomatic, persistently aPL-positive individuals do not benefit from low-dose aspirin for primary thrombosis prophylaxis, have a low overall annual incidence rate of acute thrombosis, and develop vascular events when additional thrombosis risk factors are present.

Integrity signals

Registry

Crossref · 10.1002/art.22663

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Self-citation
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update
Pearson, T. A., Blair, S. N., Daniels, S. R., Eckel, R. H., Fair, J. M., Fortmann, S. P., Franklin, B. A., Goldstein, L. B., Greenland, P., Grundy, S. M., et al. (2002) · Circulation · doi:10.1161/01.cir.0000020190.45892.75 · Cited by 1,837
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Primary Prevention of Ischemic Stroke
Goldstein, L. B., Adams, R. J., Alberts, M. J., Appel, L. J., Brass, L. M., Bushnell, C., Culebras, A., DeGraba, T. J., Gorelick, P. B., Guyton, J. R., et al. (2006) · Stroke · doi:10.1161/01.str.0000223048.70103.f1 · Cited by 1,376
Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH.
Brandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164
Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial
Pulmonary Embolism Prevention (PEP) trial Collaborative Group (2000) · The Lancet · doi:10.1016/s0140-6736(00)02110-3 · Cited by 1,076
Criteria for the Diagnosis of Lupus Anticoagulants: An Update: On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH
Brandt, J. T., Triplett, D. A., Alving, B., & Scharrer, I. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649901 · Cited by 993
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 972

Flagged first, then by citations

Show all 46 references

Research works printed but not linked: 2

Papadopolous E, 1999, Antiphospholipid antibodies and venous thrombosis (VT) in SLE, Arthritis Rheum, 42, S369
Kaul M, 2006, Assessment of the 2006 revised antiphospholipid syndrome (APS) classification criteria, Arthritis Rheum, 54, S796

Sorted by citations

Untitled work
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
Guidelines for the Primary Prevention of Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Goldstein, L. B., Bushnell, C. D., Adams, R. J., Appel, L. J., Braun, L. T., Chaturvedi, S., Creager, M. A., Culebras, A., Eckel, R. H., Hart, R. G., et al. (2011) · Stroke · doi:10.1161/str.0b013e3181fcb238 · Cited by 1,306
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramón, E., Buonaiuto, V, Jacobsen, S., Zeher, M. M., Tarr, T., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204838 · Cited by 974
Antiphospholipid syndrome
Ruiz‐Irastorza, G., Crowther, M. A., Branch, W. D., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 875
Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments
Antar, S. A., Ashour, N. A., Sharaky, M. M., Khattab, M., Ashour, N. A., Zaid, R. T., Roh, E. J., Elkamhawy, A., & Al-Karmalawy, A. A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115734 · Cited by 812
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task Force of the EULAR standing Committee for clinical Affairs
Bertsias, G. K., Ioannidis, J. P. A., Aringer, M., Bollen, E., Bombardieri, S., Bruce, I. N., Cervera, R., Dalakas, M., Doria, A., Hanly, J. G., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.130476 · Cited by 742
Guidelines on the investigation and management of antiphospholipid syndrome
Keeling, D., Mackie, I., Moore, G. W., Greer, I. A., Greaves, M., & British Committee for Standards in Haematology (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09037.x · Cited by 740
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task Force at the 13th International Congress on antiphospholipid antibodies
Ruiz-Irastorza, G., Cuadrado, M., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V, et al. (2011) · Lupus · doi:10.1177/0961203310395803 · Cited by 506
Self-citation
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study
Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., De Micheli, V., Gresele, P., Tonello, M., Ghirarduzzi, A., et al. (2011) · Blood · doi:10.1182/blood-2011-03-340232 · Cited by 468
Antiphospholipid syndrome
Schreiber, K. I., Sciascia, S., de Groot, P. G., Devreese, K. M. J., Jacobsen, S., Ruiz‐Irastorza, G., Salmon, J. E., Shoenfeld, Y., Shovman, O., & Hunt, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.103 · Cited by 445
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies
Tektonidou, M. G., Laskari, K., Panagiotakos, D. B., & Moutsopoulos, H. M. (2009) · Arthritis Care & Research · doi:10.1002/art.24232 · Cited by 356
Diagnosis and classification of the antiphospholipid syndrome
Gómez-Puerta, J. A., & Cervera, R. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.01.006 · Cited by 301
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients
Cervera, R., Khamashta, M. A., Shoenfeld, Y., Camps, M. T., Jacobsen, S., Kiss, E., Zeher, M. M., Tincani, A., Kontopoulou-Griva, I., Galeazzi, M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.093179 · Cited by 286
Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management
Knight, J. S., Branch, D. W., & Ortel, T. L. (2023) · BMJ · doi:10.1136/bmj-2021-069717 · Cited by 299
Antiphospholipid syndrome
Cervera, R. (2017) · Thrombosis Research · doi:10.1016/s0049-3848(17)30066-x · Cited by 261
Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis
Arnaud, L., Mathian, A., Ruffatti, A., Erkan, D., Tektonidou, M., Cervera, R., Forastiero, R., Pengo, V., Lambert, M., Martinez-Zamora, M. A., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.10.014 · Cited by 215
Self-citation
The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus
Ünlü, O., Zuily, S., & Erkan, D. (2015) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2015.0085 · Cited by 212
Self-citation
Antiphospholipid syndrome
Sammaritano, L. R. (2019) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.101463 · Cited by 211
Self-citation
Diagnosis and management of the antiphospholipid syndrome
Chaturvedi, S., & McCrae, K. R. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.07.006 · Cited by 195
New therapeutic strategies in systemic lupus erythematosus management
Gatto, M., Zen, M., Iaccarino, L., & Doria, A. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0133-2 · Cited by 186
Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis
Reynaud, Q., Lega, J.-C., Mismetti, P., Chapelle, C., Wahl, D., Cathébras, P., & Laporte, S. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.11.004 · Cited by 179
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends
Cohen, H., Cuadrado, M. J., Erkan, D., Duarte‐García, A., Isenberg, D. A., Knight, J. S., Ortel, T. L., Rahman, A., Salmon, J. E., Tektonidou, M. G., et al. (2020) · Lupus · doi:10.1177/0961203320950461 · Cited by 170
Self-citation
Pre-eclampsia in low and middle income countries
Firoz, T., Sanghvi, H., Merialdi, M., & von Dadelszen, P. (2011) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2011.04.002 · Cited by 161
Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus
Capodanno, D., & Angiolillo, D. J. (2016) · Circulation · doi:10.1161/circulationaha.116.023164 · Cited by 158
Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade
Bertsias, G. K., Salmon, J. E., & Boumpas, D. T. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.135186 · Cited by 152
Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies
Arnaud, L., Mathian, A., Devilliers, H., Ruffatti, A., Tektonidou, M., Forastiero, R., Pengo, V., Lambert, M., Lefevre, G., Martinez-Zamora, M. A., et al. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.10.019 · Cited by 146
An update on mortality in systemic lupus erythematosus.
Ippolito, A., & Petri, M. (2008) · PubMed · Cited by 131
Self-citation
Persistent Antiphospholipid Antibody (APL) in Asymptomatic Carriers as a Risk Factor for Future Thrombotic Events: A Nationwide Prospective Study
Mustonen, P., Lehtonen, K. V., Javela, K., & Puurunen, M. (2014) · Lupus · doi:10.1177/0961203314545410 · Cited by 127
Pathogenesis and management of antiphospholipid syndrome
Arachchillage, D. J., & Laffan, M. (2017) · British Journal of Haematology · doi:10.1111/bjh.14632 · Cited by 125
REVISTA BRASILEIRA DE REUMATOLOGIA
Danowski, A., & Levy, R. A. (2013) · Cited by 116
Self-citation
Partially randomised patient preference trials as an alternative design to randomised controlled trials: systematic review and meta-analyses
Wasmann, K. A. T. G. M., Wijsman, P. C., van Dieren, S., Bemelman, W. A., & Buskens, C. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031151 · Cited by 120
Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study
Gris, J., Bouvier, S., Molinari, N., Galanaud, J. ‐., Cochery-Nouvellon, É., Mercier, É., Fabbro-Péray, P., Balducchi, J.-P., Marès, P., Quéré, I., et al. (2011) · Blood · doi:10.1182/blood-2011-09-381913 · Cited by 108
Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study
Ruffatti, A., Ross, T. D., Ciprian, M., Nuzzo, M., Rampudda, M., Bertero, M. T., Bergia, R., Caramaschi, P., Biasi, D., Capsoni, F., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.096669 · Cited by 106
Antiphospholipid syndrome
Petri, M. (2020) · Translational research · doi:10.1016/j.trsl.2020.04.006 · Cited by 113
Self-citation
Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults
Tektonidou, M. G., Andréoli, L., Limper, M., Tincani, A., & Ward, M. M. (2019) · RMD Open · doi:10.1136/rmdopen-2019-000924 · Cited by 101
Aspirin for the Primary Prevention of Cardiovascular Events
Calvin, A. D., Aggarwal, N. R., Murad, M. H., Shi, Q., Elamin, M. B., Geske, J. B., Fernández-Balsells, M., Albuquerque, F. N., Lampropulos, J. F., Erwin, P. J., et al. (2009) · Diabetes Care · doi:10.2337/dc09-1297 · Cited by 98
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)
Cuadrado, M. J., Bertolaccini, M. L., Seed, P. T., Tektonidou, M. G., Aguirre, A., Micó, L., Gordon, C., Ruiz‐Irastorza, G., Egurbide, M.-V., Gil, A., et al. (2013) · Rheumatology · doi:10.1093/rheumatology/ket313 · Cited by 92
Cutaneous Manifestations of Antiphospholipid Antibody Syndrome
Weinstein, S., & Piette, W. W. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.10.011 · Cited by 88
Antiphospholipid syndrome – an update
Linnemann, B. (2018) · VASA · doi:10.1024/0301-1526/a000723 · Cited by 86
Aspirin for Primary Prevention of Cardiovascular Events: Meta-Analysis of Randomized Controlled Trials and Subgroup Analysis by Sex and Diabetes Status
Xie, M., Shan, Z., Zhang, Y., Chen, S., Yang, W., Bao, W., Rong, Y., Yu, X., Hu, F. B., & Liu, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090286 · Cited by 84
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients
Hereng, T., Lambert, M., HACHULLA, E., Samor, M., Dubucquoi, S., Caron, C., Launay, D., Morell‐Dubois, S., Queyrel, V., & Hatron, P. (2007) · Lupus · doi:10.1177/0961203307084724 · Cited by 84
How I treat the antiphospholipid syndrome
Giannakopoulos, B., & Krilis, S. A. (2009) · Blood · doi:10.1182/blood-2009-05-220756 · Cited by 83
Pediatric Antiphospholipid Syndrome
Cimaz, R., & Descloux, É. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.05.005 · Cited by 81
Venous Thrombosis in the Antiphospholipid Syndrome
Farmer-Boatwright, M. K., & Roubey, R. A. S. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.182204 · Cited by 82
Management of antiphospholipid syndrome
Tuthill, J. I., & Khamashta, M. A. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.05.002 · Cited by 78
Frequency of Intracranial Hemorrhage With Low-Dose Aspirin in Individuals Without Symptomatic Cardiovascular Disease
Huang, W., Saver, J. L., Wu, Y., Lin, C., Lee, M., & Ovbiagele, B. I. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1120 · Cited by 80
Guidelines on the investigation and management of antiphospholipid syndrome
Arachchillage, D. J., Platton, S., Hickey, K. P., Chu, J., Pickering, M. C., Sommerville, P., MacCallum, P., & Breen, K. A. (2024) · British Journal of Haematology · doi:10.1111/bjh.19635 · Cited by 77
Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long‐term follow‐up study of patients without history of thrombosis or obstetrical morbidity
Yelnik, C. M., Urbanski, G., Drumez, E., Sobanski, V, Maillard, H., Lanteri, A., Morell-Dubois, S., Caron, C., Dubucquoi, S., Launay, D., et al. (2017) · Lupus · doi:10.1177/0961203316657433 · Cited by 73
Ocular manifestations of the antiphospholipid syndrome
Utz, V. M., & Tang, J. C. O. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.182857 · Cited by 72
New approaches for managing antiphospholipid syndrome
Erkan, D., & Lockshin, M. D. (2009) · Nature Reviews Rheumatology · doi:10.1038/ncprheum1017 · Cited by 71
Self-citation
Antiphospholipid Syndrome
George, D., & Erkan, D. (2009) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.06.005 · Cited by 71
Self-citation
Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?
Barbhaiya, M., & Erkan, D. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-010-0149-3 · Cited by 69
Self-citation
Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease
Erkan, D., Unlu, O., Sciascia, S., Belmont, H. M., Branch, D. W., Cuadrado, M. J., Gonzalez, E., Knight, J. S., Uthman, I., Willis, R., et al. (2018) · Lupus · doi:10.1177/0961203317724219 · Cited by 66
Self-citation
Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management—An Insight into Future Approaches
Chighizola, C. B., Ubiali, T., & Meroni, P. L. (2015) · Journal of Immunology Research · doi:10.1155/2015/951424 · Cited by 67
The treatment of anti-phospholipid syndrome: A comprehensive clinical approach
Chighizola, C. B., Andréoli, L., Gerosa, M., Tincani, A., Ruffatti, A., & Meroni, P. L. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.02.003 · Cited by 66
Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach
Ambati, A., Knight, J. S., & Zuo, Y. (2023) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000932 · Cited by 68
Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies
Kim, K., Baek, I., Yoon, C., Kim, W., & Cho, C. (2013) · British Journal of Haematology · doi:10.1111/bjh.12318 · Cited by 65
Recent advances in the diagnosis and management of neuropsychiatric lupus
Legge, A. C., & Hanly, J. G. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01163-z · Cited by 66
Lupus: improving long-term prognosis
Doria, A., & Briani, C. (2008) · Lupus · doi:10.1177/0961203307087612 · Cited by 58
Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?
Pierangeli, S., & Erkan, D. (2010) · Lupus · doi:10.1177/0961203310361489 · Cited by 56
Self-citation
Antiphospholipid syndrome and the brain in pediatric and adult patients
Muscal, E., & Brey, R. L. (2010) · Lupus · doi:10.1177/0961203309360808 · Cited by 56
Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a case–control study
Martínez‐Zamora, M. Á., Peralta, S., Creus, M. T., Tàssies, D., Reverter, J. C., Espinosa, G., Cervera, R., Carmona, F., & Balasch, J. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.153817 · Cited by 54
Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010
Branch, W. D. (2011) · Lupus · doi:10.1177/0961203310395054 · Cited by 53
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Bała, M. M., Celińska‐Löwenhoff, M., Szot, W., Padjas, A., Kaczmarczyk, M., Świerz, M. J., & Undas, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012169.pub2 · Cited by 53
The antiphospholipid syndrome: still an enigma
Chaturvedi, S., & McCrae, K. R. (2015) · Hematology · doi:10.1182/asheducation-2015.1.53 · Cited by 51
Management of Antiphospholipid Syndrome
Ghembaza, A., & Saadoun, D. (2020) · Biomedicines · doi:10.3390/biomedicines8110508 · Cited by 50
Antiphospholipid syndrome: state of the art on clinical practice guidelines
Limper, M., Scirè, C. A., Talarico, R., Amoura, Z., Avčin, T., Basile, M., Burmester, G. R., Carli, L., Cervera, R., Costedoat-Chalumeau, N., et al. (2018) · RMD Open · doi:10.1136/rmdopen-2018-000785 · Cited by 50
Antiphospholipid antibodies — We are not quite there yet
Urbanus, R. T., & de Groot, P. G. (2011) · Blood Reviews · doi:10.1016/j.blre.2010.12.001 · Cited by 48
D-Dimer Level and the Risk for Thrombosis in Systemic Lupus Erythematosus
Wu, H. M., Birmingham, D. J., Rovin, B. H., Hackshaw, K. V., Haddad, N. F., Haden, D. W., Yu, C. Y., & Hebert, L. A. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01480308 · Cited by 47
Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies
Bała, M. M., Paszek, E., Leśniak, W., Włoch-Kopeć, D., Jasińska, K., & Undas, A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012534.pub2 · Cited by 47
Membranous Lupus Nephritis: A Clinical Review
Almaani, S. J., & Parikh, S. V. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.009 · Cited by 47
Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study
Iudici, M., Fasano, S., Falcone, L. G., Pantano, I., MONTAGNA, G. L., Migliaresi, S., & Valentini, G. (2016) · Rheumatology · doi:10.1093/rheumatology/kew231 · Cited by 46
Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study
de Jesús, G., Sciascia, S., Andrade, D., Barbhaiya, M., Tektonidou, M., Banzato, A., Pengo, V, Ji, L., Meroni, P., Ugarte, A., et al. (2019) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15469 · Cited by 45
Self-citation
Grossesse et syndrome des antiphospholipides
Costedoat-Chalumeau, N., Guettrot-Imbert, G., Guern, V. L., Leroux, G., Huong, D. U. L. T., Wechsler, B., Morel, N., Vauthier-Brouzes, D., Dommergues, M., Cornet, A., et al. (2012) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2012.01.003 · Cited by 45
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Bała, M. M., Celińska‐Löwenhoff, M., Szot, W., Padjas, A., Kaczmarczyk, M., Świerz, M. J., & Undas, A. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012169.pub3 · Cited by 46
Clinical Management of Thrombotic Antiphospholipid Syndrome
Tumian, N. R., & Hunt, B. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030735 · Cited by 45
Inhibition of Nitric Oxide and Antiphospholipid Antibody-Mediated Thrombosis
Mineo, C. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0324-4 · Cited by 43
Thrombophilia testing in young patients with ischemic stroke
Pahus, S. H., Hansen, A. T., & Hvas, A. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.11.006 · Cited by 43
Design and rationale of a Prospective, Observational European Multicenter study on the efficacy of acute surgical decompression after traumatic Spinal Cord Injury: the SCI-POEM study
van Middendorp, J. J., Barbagallo, G. M. V., Schuetz, M., & Hosman, A. J. F. (2012) · Spinal Cord · doi:10.1038/sc.2012.34 · Cited by 40
The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome
Wincup, C., & Ioannou, Y. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00362 · Cited by 39
Pediatric Antiphospholipid Syndrome
Aguiar, C. L., Soybilgic, A., Avčin, T., & Myones, B. L. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-015-0504-5 · Cited by 39
Treatment of the antiphospholipid syndrome
Galli, M. (2013) · Autoimmunity Highlights · doi:10.1007/s13317-013-0056-5 · Cited by 38
Clinical Features, Diagnosis, and Management of the Antiphospholipid Syndrome
Wong, R. C. W., & Favaloro, E. J. (2008) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0028-1082275 · Cited by 38
Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: Benefit or risk?
Leggio, M., Bendini, M. G., Caldarone, E., Lombardi, M., Severi, P., D’Emidio, S., Stavri, D. C., Armeni, M., Bravi, V., & Mazza, A. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.11.002 · Cited by 37
Prevalence of Antiphospholipid Antibodies and Association With Incident Cardiovascular Events
Zuo, Y., Navaz, S. A., Liang, W., Li, C., Ayers, C. R., Rysenga, C. E., Harbaugh, A., Norman, G. L., Solow, E. B., Bermas, B. L., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.6530 · Cited by 37
Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies
Watanabe, T., Oku, K., Amengual, O., Hisada, R., Ohmura, K., Nakagawa, I., Shida, H., Bohgaki, T., Horita, T., Yasuda, S., et al. (2017) · Lupus · doi:10.1177/0961203317716787 · Cited by 38
Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention in Younger and Older Age: An Updated Systematic Review and Meta-analysis of 173,810 Subjects from 21 Randomized Studies
Calderone, D., Greco, A., Ingala, S., Agnello, F. G., Franchina, A. G., Scalia, L., Buccheri, S., & Capodanno, D. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1667-7427 · Cited by 37
Anticardiolipin antibodies and recurrent early pregnancy loss: a century of equivocal evidence
Clark, C. A., Laskin, C. A., & Spitzer, K. A. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms020 · Cited by 37
Neurologic manifestations of the antiphospholipid syndrome: Integrating molecular and clinical lessons
Muscal, E., & Brey, R. L. (2008) · Current Rheumatology Reports · doi:10.1007/s11926-008-0012-y · Cited by 37
Antiphospholipid syndrome: a clinical perspective
Zuo, Y., Shi, H., Li, C., & Knight, J. S. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000705 · Cited by 39
Pharmacotherapy of systemic lupus erythematosus
Francis, L., & Perl, A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902971003 · Cited by 35
16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome
de Jesús, G. R., Benson, A. E., Chighizola, C. B., Sciascia, S., & Branch, D. W. (2020) · Lupus · doi:10.1177/0961203320954520 · Cited by 37
Seizures in Primary Antiphospholipid Syndrome: The Relevance of Smoking to Stroke
de Carvalho, J. F., Pasoto, S. G., & Appenzeller, S. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/981519 · Cited by 35
High Prevalence of Prothrombotic Abnormalities in Multifocal Osteonecrosis
Gómez-Puerta, J. A., Peris, P., Reverter, J. C., Espinosa, G., Martinez-Ferrer, A., Monegal, A., Ruiz, J. M. M., Tàssies, D., & Guañabens, N. (2013) · Medicine · doi:10.1097/md.0000000000000007 · Cited by 35
Persistent antiphospholipid antibodies do not contribute to adverse pregnancy outcomes
Soh, M. C., Pasupathy, D., Gray, G., & Nelson‐Piercy, C. (2013) · Rheumatology · doi:10.1093/rheumatology/ket173 · Cited by 35
Transient ischemic attack and stroke in systemic lupus erythematosus
Timlin, H., & Petri, M. (2013) · Lupus · doi:10.1177/0961203313497416 · Cited by 35
Self-citation
Thrombosis in systemic lupus erythematosus: risk and protection
Burgos, P. I., & Alarcón, G. S. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.137 · Cited by 34
Anti‐β2‐glycoprotein I antibodies
Willis, R., & Pierangeli, S. S. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12080 · Cited by 34
Primary and secondary prevention of cardiovascular disease in diabetes with aspirin
Schnell, O., Erbach, M., & Hummel, M. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441486 · Cited by 33

Authors: Erkan, D., Harrison, M. J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., Unalp‐Arida, A., Vilela, V., Yazici, Y., & Lockshin, M. D.
Affiliations: Hospital for Special Surgery (US)
Hospital Universitário Pedro Ernesto (BR)
Johns Hopkins University (US)
ORCID: Erkan, Doruk
Levy, Roger
Petri, Michelle
Sammaritano, Lisa
Lockshin, Michael D.
Venue: Arthritis & Rheumatism
Publisher: Wiley
Published: 2007-06-28
Volume: 56
Issue: 7
Pages: 2382-2391
ISSN: 0004-3591 (ISSN-L)
1529-0131
DOI: 10.1002/art.22663
OpenAlex: W2068492012
Cited by: 401
References: 46
Citations by year: 2026: 5 · 2025: 8 · 2024: 12 · 2023: 16 · 2022: 10 · 2021: 16 · 2020: 16 · 2019: 18 · 2018: 19 · 2017: 23 · 2016: 24 · 2015: 16 · 2014: 27 · 2013: 32 · 2012: 37
FWCI: 21.25
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Arthritis & Rheumatism (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords: aspirin, antiphospholipid syndrome, antiphospholipid antibodies, thromboprophylaxis, low-dose aspirin, thrombosis risk factors, vascular events
MeSH terms: Adult, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Double-Blind Method, Ethnicity, Female, Humans, Male, Middle Aged, Placebos, Thrombosis, Antiphospholipid Syndrome, Patient Selection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo controlled trial in asymptomatic antiphospholipid antibody-positive individuals.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks